Suppr超能文献

维多利亚运动评估-跟腱(VISA-A)问卷:活跃的中段跟腱病患者的最小临床重要差异:一项前瞻性队列研究

Victorian Institute of Sport Assessment-Achilles (VISA-A) Questionnaire-Minimal Clinically Important Difference for Active People With Midportion Achilles Tendinopathy: A Prospective Cohort Study.

作者信息

Lagas Iris F, van der Vlist Arco C, van Oosterom Robert F, van Veldhoven Peter L J, Reijman Max, Verhaar Jan A N, de Vos Robert-Jan

出版信息

J Orthop Sports Phys Ther. 2021 Oct;51(10):510-516. doi: 10.2519/jospt.2021.10040.

Abstract

OBJECTIVE

To determine the minimal clinically important difference (MCID) for the Victorian Institute of Sport Assessment-Achilles (VISA-A) score in patients with midportion Achilles tendinopathy (AT).

DESIGN

Prospective cohort study.

METHODS

We included physically active patients with midportion AT who received exercises and an injection. We measured the VISA-A score (ranging from 0 to 100 points, where 100 points represents a healthy tendon) at baseline and at 12 weeks and 24 weeks after treatment, and the 7-point Global Assessment Scale (ranging from "worse than ever" to "completely recovered") at 12 weeks and 24 weeks after treatment. We dichotomized the Global Assessment Scale to not improved ("worse than ever" to "unchanged") or improved ("moderately improved" to "completely recovered"). The area under the curve and the Youden's index value closest to 1 were determined for both MCIDs (12 and 24 weeks), with corresponding sensitivity and specificity.

RESULTS

Sixty-four patients were included, and 61 patients (95%) completed the 24-week follow-up. The MCID was 14 points (95% confidence interval [CI]: 3, 19) over a 12-week period, corresponding to 57% sensitivity and 88% specificity. The MCID was 7 points (95% CI: -10, 28) over a 24-week period, with 85% sensitivity and 62% specificity.

CONCLUSION

A change in VISA-A score of at least 14 points after 12 weeks or at least 7 points after 24 weeks of exercise therapy and an injection reflects a meaningful change for physically active patients with midportion AT. .

摘要

目的

确定维多利亚运动评估-跟腱(VISA-A)评分在中部跟腱病(AT)患者中的最小临床重要差异(MCID)。

设计

前瞻性队列研究。

方法

我们纳入了接受运动和注射治疗的有运动能力的中部AT患者。在基线、治疗后12周和24周测量VISA-A评分(范围为0至100分,其中100分代表健康肌腱),并在治疗后12周和24周测量7分全球评估量表(范围从“比以往更差”到“完全恢复”)。我们将全球评估量表分为未改善(“比以往更差”到“无变化”)或改善(“中度改善”到“完全恢复”)。确定两个MCID(12周和24周)的曲线下面积和最接近1的约登指数值,以及相应的敏感性和特异性。

结果

纳入64例患者,61例(95%)完成了24周随访。12周期间的MCID为14分(95%置信区间[CI]:3,19),对应敏感性为57%,特异性为88%。24周期间的MCID为7分(95%CI:-10,28),敏感性为85%,特异性为62%。

结论

运动疗法和注射治疗12周后VISA-A评分至少改变14分或24周后至少改变7分,反映了有运动能力的中部AT患者有意义的变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验